Ready for Prime Time?
Is routine adoption of AI-assisted colonoscopy ready for prime time? Glissen Brown thinks so, with some caveats.
Duke University Medical Center
Dr. Jeremy R. Glissen Brown
“We are at a pivotal point in the examination CADe for routine use in colonoscopy. CADe has been ready for prime time in the United States since at least 2021, and the study of CADe has made the field of gastroenterology a clinical leader when it comes to the number of high-quality randomized trials examining AI interventions,” Glissen Brown said.
However, outside of the clinical trial setting, questions about successful deployment and implementation remain, he said.
“These include but are in no way limited to ways to optimize the AI-human interaction in order to produce a successful AI-provider partnership, issues of reimbursement and cost, and issues of ethical AI development and deployment,” Glissen Brown said.
“We also need to continue to assess methods of estimating CADe use on the downstream outcomes that matter, such as the effects of CADe on reducing rates of colon cancer, rates of post-colonoscopy colorectal cancer (CRC), and the effect that CADe might have on CRC-related mortality. In addition, more studies on the patient voice and patient preference as it relates to AI use are greatly needed,” Glissen Brown said.
The American Gastroenterological Association has drafted recommendations on the use of CADe systems during colonoscopy. Clinicians are invited to review the draft guideline and share feedback during the public comment period, which ended on October 28.
The study had no specific funding. Disclosures for study authors are available with the original article. Glissen Brown is a consultant for Medtronic, Olympus, and Odin Vision. He was also the lead author on one of the studies included in the meta-analysis (Clin Gastroenterol Hepatol. 2022 Jul;20[7]:1499.e4-1507.e4).
A version of this article appeared on Medscape.com.
